The Carlyle Group and Hellman & Friedman have completed their $3.9 billion acquisition of PPD (NYSE:PPDI). The private equity firms announced the completion of the all-cash deal for the clinical research organization today. The close follows an approval vote from shareholders last week. At the Nov. 30 shareholders meeting at PPD’s Wilmington, North Carolina headquarters, […]
PPD (NYSE:PPDI), among the largest clinical research organizations in the industry, is on its way to becoming a private company. Shareholders voted to approve the $3.9 billion sale of the Wilmington, North Carolina-based CRO to private equity firms The Carlyle Group and Hellman & Friedman. PPD said that more than 96 percent of shares voting […]
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
Any PPD (NYSE:PPDI) shareholders with something to say about the $3.9 billion sale of the clinical research organization will probably be making their way today to the coastal city of Wilmington, North Carolina. At PPD’s global headquarters, the CRO has scheduled a meeting for shareholders to vote whether to approve the sale to private equity […]
PPD (NYSE:PPDI) will have no other acquirers trying to top the $3.9 billion bid for the clinical research organization from private equity firms The Carlyle Group and Hellman & Friedman. Just one party entered into the same confidentiality agreements that Carlyle and H&F agreed to in order to begin acquisition talks with the CRO. But […]
Days before PPD‘s (NYSE:PPDI) $3.9 billion sale to private equity was announced on October 3, the clinical research organization’s lead independent director, Ernest Mario, was busy trading e-mails and phone calls with The Carlyle Group in an effort to improve what had become a substantially reduced offer. Carlyle and Hellman & Friedman, the other private […]
PPD‘s (NYSE:PPDI) $3.9 billion sale to The Carlyle Group and Hellman & Friedman offered shareholders of the clinical research organization a nearly 30 percent premium over the company’s closing stock price before the private equity deal was announced. But www.footnoted.com, a unit of Morningstar that looks for hidden items buried in securities filings, suggested that […]
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
PPD‘s (NYSE:PPDI) founder and former CEO Fred Eshelman launched Pharmaceutical Product Development out of his Maryland home in 1985. Twenty six years later, the company Eshelman started as a one-man consultancy is set to be sold for just shy of $4 billion. Wilmington, North Carolina clinical research organization PPD announced today private equity firms The […]
PPD‘s (NYSE:PPDI) $3.9 billion acquisition by private equity firms The Carlyle Group and Hellman & Friedman is just the latest in a growing string of private equity deals involving clinical research organizations. Activity in the CRO space is being driven by its growth: the CRO business has grown and is projected to grow even more […]
North Carolina clinical research organization PPD (NYSE:PPDI) will be acquired by two private equity firms in a $3.9 billion cash deal that will take the CRO private. PPD announced the definitive merger agreement with The Carlyle Group and Hellman & Friedman Monday. The sale price comes to $33.25 per share, a 29.6 percent premium over […]
PPD‘s (NYSE:PPDI) new CEO Ray Hill doesn’t come from a clinical research organization, but his experience fits with where the CRO industry is going. IMS Health provides data and research for pharmaceutical companies and others in the health space. As a provider of research and services to pharma companies, IMS’ work is not far off […]
3D medical animation services have emerged as a groundbreaking tool in the healthcare industry, revolutionizing the way medical concepts are taught, understood, and marketed.
PPD‘s (NYSE:PPDI) new CEO brings the clinical research organization a long track record in healthcare and life sciences consulting. Raymond Hill comes to Wilmington, North Carolina-based PPD from research and consulting firm IMS Health, where he has worked for the past eight years. His appointment as PPD CEO and member of the CRO’s board of […]
Clinical research organization PPD (NYSE:PPDI) has appointed a chief scientific officer for BioDuro, its drug discovery subsidiary in China. Jasmine Cui brings to PPD more than 15 years of drug discovery experience, including 14 years at Merck (NYSE:MRK). Wilmington, North Carolina-based PPD has made China a big part of its business through acquisitions. In 2009, […]
Clinical research organization PPD (NYSE:PPDI) is talking with private equity firm The Carlyle Group about an M&A deal. Bloomberg News reports that Carlyle is in exclusive talks to possibly acquire Wilmington, North Carolina-based PPD, which is the third-largest CRO in the industry with more than $1.4 billion in 2010 revenue. Bloomberg cited five unnamed sources […]
PPD (NYSE:PPDI) released second-quarter earnings today and in the conference call to follow Wednesday morning, I would bet on at least two questions analysts will pose to management of the North Carolina clinical research organization: How is the search progressing for a new CEO to replace retired CEO David Grange? Is PPD in talks with […]
Talk of whether PPD (NYSE:PPDI) is for sale has prompted the clinical research organization to publicly state it not in talks with any other CRO regarding a merger or acquisition. But Wilmington, North Carolina-based PPD did say that its board of directors has asked management to review the company’s strategic plan and capital structure “with […]